Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Has results × brolucizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1 Macular Degeneration 1

Interventions

Cyclophosphamide 800 Carboplatin 687 Paclitaxel 645 Bevacizumab 632 Cisplatin 606 pembrolizumab 605 Gemcitabine 539 Docetaxel 499 Rituximab 485 Radiotherapy 482 Dexamethasone 440 Nivolumab 412 Doxorubicin 391 Fluorouracil 342 Capecitabine 336 Etoposide 315 Oxaliplatin 292 Cytarabine 291 Prednisone 289 Pemetrexed 288 Lenalidomide 286 fludarabine phosphate 277 Erlotinib Hydrochloride 274 Leucovorin 266 fludarabine 261 Trastuzumab 255 Filgrastim 252 Vincristine 251 Bortezomib 249 Irinotecan 235

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡